File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Determination of free bilirubin and its binding capacity by HSA using a microfluidic chip-capillary electrophoresis device with a multi-segment circular-ferrofluid-driven micromixing injection

TitleDetermination of free bilirubin and its binding capacity by HSA using a microfluidic chip-capillary electrophoresis device with a multi-segment circular-ferrofluid-driven micromixing injection
Authors
KeywordsBinding capacity
Circular-ferrofluid-driven micromixer
Free bilirubin
HSA
Residual binding capacity
Issue Date2010
Citation
Electrophoresis, 2010, v. 31 n. 18, p. 3061-3069 How to Cite?
AbstractA PMMA microfluidic chip-CE device with a multi-segment circular-ferrofluid-driven micromixing injector has been developed for the determination of free bilirubin and its binding capacity by HSA at equilibrium. The design of the device and its fabrication by a low cost CO2 laser are discussed for intended applications. Under optimized conditions, the total binding capacity of HSA for bilirubin was determined as 16.3±1.4 mg/l00 mL human serum (n=3) and residual binding capacity for bilirubin 9.8 mg/l00 mL (n=3) in normal infants. To assess risk of hyperbilirubinemia, free bilirubin and residual binding capacity by HSA provide a better indicator than total bilirubin, as neonates with impaired bilirubin binding capacity could be detected. In addition, residual binding capacity provides an advanced indicator to predict the onset of hyperbilirubinemia before the appearance of free bilirubin. HSA down to 94 nL is used in each titration and a full assay of four titrations takes up 376 nL HSA, sufficient for newborns with HSA in microliter range. The device has shown capable to provide adequate margin of protection to detect an early rising level of bilirubin and impaired binding capacity prior to the onset of jaundice condition. © 2010 Wiley-VCH Verlag GmbH & Co. KGaA.
Persistent Identifierhttp://hdl.handle.net/10722/168475
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 0.541
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSun, Hen_US
dc.contributor.authorNie, Zen_US
dc.contributor.authorFung, YSen_US
dc.date.accessioned2012-10-08T03:19:25Z-
dc.date.available2012-10-08T03:19:25Z-
dc.date.issued2010en_US
dc.identifier.citationElectrophoresis, 2010, v. 31 n. 18, p. 3061-3069en_US
dc.identifier.issn0173-0835en_US
dc.identifier.urihttp://hdl.handle.net/10722/168475-
dc.description.abstractA PMMA microfluidic chip-CE device with a multi-segment circular-ferrofluid-driven micromixing injector has been developed for the determination of free bilirubin and its binding capacity by HSA at equilibrium. The design of the device and its fabrication by a low cost CO2 laser are discussed for intended applications. Under optimized conditions, the total binding capacity of HSA for bilirubin was determined as 16.3±1.4 mg/l00 mL human serum (n=3) and residual binding capacity for bilirubin 9.8 mg/l00 mL (n=3) in normal infants. To assess risk of hyperbilirubinemia, free bilirubin and residual binding capacity by HSA provide a better indicator than total bilirubin, as neonates with impaired bilirubin binding capacity could be detected. In addition, residual binding capacity provides an advanced indicator to predict the onset of hyperbilirubinemia before the appearance of free bilirubin. HSA down to 94 nL is used in each titration and a full assay of four titrations takes up 376 nL HSA, sufficient for newborns with HSA in microliter range. The device has shown capable to provide adequate margin of protection to detect an early rising level of bilirubin and impaired binding capacity prior to the onset of jaundice condition. © 2010 Wiley-VCH Verlag GmbH & Co. KGaA.en_US
dc.languageengen_US
dc.relation.ispartofElectrophoresisen_US
dc.subjectBinding capacity-
dc.subjectCircular-ferrofluid-driven micromixer-
dc.subjectFree bilirubin-
dc.subjectHSA-
dc.subjectResidual binding capacity-
dc.subject.meshBilirubin - Analysis - Blood - Metabolismen_US
dc.subject.meshElectromagnetic Fieldsen_US
dc.subject.meshElectrophoresis, Capillary - Instrumentation - Methodsen_US
dc.subject.meshFerumoxytol - Chemistryen_US
dc.subject.meshHumansen_US
dc.subject.meshHyperbilirubinemia - Diagnosisen_US
dc.subject.meshIonic Liquids - Chemistryen_US
dc.subject.meshLasers, Gasen_US
dc.subject.meshMagneticsen_US
dc.subject.meshMicrofluidic Analytical Techniques - Instrumentation - Methodsen_US
dc.subject.meshPolymethyl Methacrylate - Chemistryen_US
dc.subject.meshProtein Bindingen_US
dc.subject.meshSerum Albumin - Metabolismen_US
dc.titleDetermination of free bilirubin and its binding capacity by HSA using a microfluidic chip-capillary electrophoresis device with a multi-segment circular-ferrofluid-driven micromixing injectionen_US
dc.typeArticleen_US
dc.identifier.emailSun, H:sunhui@hku.hken_US
dc.identifier.emailFung, YS:ysfung@hku.hken_US
dc.identifier.authoritySun, H=rp00778en_US
dc.identifier.authorityFung, YS=rp00697en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/elps.200900749en_US
dc.identifier.pmid20737465-
dc.identifier.scopuseid_2-s2.0-77956903201en_US
dc.identifier.hkuros177960-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77956903201&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume31en_US
dc.identifier.issue18en_US
dc.identifier.spage3061en_US
dc.identifier.epage3069en_US
dc.identifier.isiWOS:000283389900007-
dc.publisher.placeGermanyen_US
dc.identifier.scopusauthoridSun, H=37032038600en_US
dc.identifier.scopusauthoridNie, Z=24177229900en_US
dc.identifier.scopusauthoridFung, YS=13309754700en_US
dc.identifier.issnl0173-0835-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats